12:00 AM
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Zytiga abiraterone acetate: Phase II data

An open-label, U.S. Phase II trial in 58 men with localized high-risk prostate cancer who were candidates for radical prostatectomy showed that neoadjuvant therapy with Zytiga plus leuprolide and prednisone for 24 weeks prior to surgery led to a pathological CR in 3 of 29 patients (10%) vs. 1 of 27 patients (4%) who received leuprolide alone for 12 weeks followed by Zytiga plus leuprolide and prednisone for an additional 12 weeks...

Read the full 339 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >